What Would Full FDA Approval of Pfizer's COVID Vaccine Mean for the Stock?

·3 min read

The clock is now ticking for a Food and Drug Administration decision on full approval for the COVID-19 vaccine developed by Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX). The vaccine is currently on the market in the U.S. under the FDA's Emergency Use Authorization program. In this Motley Fool Live video recorded on July 21, 2021, healthcare and cannabis bureau editor-analyst Olivia Zitkus and Motley Fool contributor Keith Speights discuss what full FDA approval might mean for Pfizer stock.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting